Bulent Ozpolat

Bulent Ozpolat, MD, PhD

Professor of Nanomedicine, Academic Institute
Full Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Biography

Dr. Bulent Ozpolat earned his PhD in Immunology from the University of Texas- Houston- MD Anderson Cancer Center, Graduate School of Biomedical Sciences (GSBS), under the guidance of Lawrence Lachman. Prior to this, he obtained his M.D. degree from Dokuz Eylul University, Izmir, Turkey. His doctoral work concentrated on DNA-vaccines against HIV, Helicobacter Pylori, and HER2+ breast cancer, employing immunoliposomes with adjuvants and interleukins. Following his PhD, he underwent postdoctoral training at MD Anderson and later served 15 years as faculty in Experimental Therapeutics. 

With over 135 peer-reviewed publications, he has received numerous research awards and holds patents. Supported by funding from NIH/NCI, US Congressionally Directed Medical Research & Department of Defense, Susan Komen, NHARP, CPRIT, and Blanton-Davis Ovarian Cancer Research Program, he also contributes as an editor and board member for scientific journals.

Description of Research

Dr. Ozpolat's research emphasizes developing targeted cancer therapies like small molecule inhibitors and microRNA-based nanotherapeutics, using tumor-targeting nanocarriers for delivering various agents. He explores novel molecular targets, non-coding RNAs, and immune therapies for solid cancers, including breast, pancreatic, lung, ovarian, and brain tumors. Notably, his work involves nanocarriers targeting survival pathways like eEF2-kinase (eEF2K), FOXM1, KRAS, and immunosuppressive pathways like PDL1 signaling.

Areas Of Expertise

Nanotechnology Immunology Drug development RNA therapeutics Gene Therapy Cancer biology and genetics Nano-therapeutics targeted therapies for oncogenic pathways
Education & Training

PhD, University of Texas at Houston Graduate School of Biomedical Sciences
Publications

The Role of Nanomedicine in Benign Gynecologic Disorders
Lulseged, BA, Ramaiyer, MS, Michel, R, Saad, EE, Ozpolat, B & Borahay, MA 2024, , Molecules (Basel, Switzerland), vol. 29, no. 9. https://doi.org/10.3390/molecules29092095

Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer
Dogra, P, Shinglot, V, Ruiz-Ramírez, J, Cave, J, Butner, JD, Schiavone, C, Duda, DG, Kaseb, AO, Chung, C, Koay, EJ, Cristini, V, Ozpolat, B, Calin, GA & Wang, Z 2024, , medRxiv. https://doi.org/10.1101/2024.03.14.24304306

SPIONs: Superparamagnetic iron oxide-based nanoparticles for the delivery of microRNAi-therapeutics in cancer
Kara, G & Ozpolat, B 2024, , Biomedical Microdevices, vol. 26, no. 1, 16, pp. 16. https://doi.org/10.1007/s10544-024-00698-y

PIM3 Kinase: A Promising Novel Target in Solid Cancers
Atalay, P & Ozpolat, B 2024, , Cancers, vol. 16, no. 3, 535. https://doi.org/10.3390/cancers16030535

Author Correction: Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer
Rodriguez-Aguayo, C, del C Monroig, P, Redis, RS, Bayraktar, E, Almeida, MI, Ivan, C, Fuentes-Mattei, E, Rashed, MH, Chavez-Reyes, A, Ozpolat, B, Mitra, R, Sood, AK, Calin, GA & Lopez-Berestein, G 2023, , Cell Discovery, vol. 9, no. 1, 111, pp. 111. https://doi.org/10.1038/s41421-023-00611-6

Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer
Cave, J, Shinglot, V, Butner, JD, Cristini, V, Ozpolat, B, Calin, GA, Dogra, P & Wang, Z 2023, , Paper presented at 45th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Sydney, Australia, 7/24/23 - 7/27/23.

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
Dilmac, S & Ozpolat, B 2023, , Cancers, vol. 15, no. 14, 3642. https://doi.org/10.3390/cancers15143642

Therapeutic Landscape of AXL Receptor Kinase in Triple Negative Breast Cancer
Ozyurt, R & Ozpolat, B 2023, , Molecular Cancer Therapeutics, vol. 22, no. 7, pp. 818-832. https://doi.org/10.1158/1535-7163.MCT-22-0617

Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer
Cave, J, Shinglot, V, Butner, JD, Cristini, V, Ozpolat, B, Calin, GA, Dogra, P & Wang, Z 2023, , Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, vol. 2023, pp. 1-4. https://doi.org/10.1109/EMBC40787.2023.10341114

SCN5A promotes the growth and lung metastasis of triple-negative breast cancer through EF2-kinase signaling
Erdogan, MA, Yuca, E, Ashour, A, Gurbuz, N, Sencan, S & Ozpolat, B 2023, , Life sciences, vol. 313, 121282, pp. 121282. https://doi.org/10.1016/j.lfs.2022.121282

Flavopiridol Suppresses Cell Proliferation and Migration and Induces Apoptotic Cell Death by Inhibiting Oncogenic FOXM1 Signaling in IDH Wild-Type and IDH-Mutant GBM Cells
Guler, A, Hamurcu, Z, Ulutabanca, H, Cinar, V, Nurdinov, N, Erdem, S & Ozpolat, B 2023, , Molecular Neurobiology, vol. 61, no. 2, pp. 1061-1079. https://doi.org/10.1007/s12035-023-03609-z

Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies
Ozyurt, R & Ozpolat, B 2022, , Cancers, vol. 14, no. 21, 5206. https://doi.org/10.3390/cancers14215206

BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer
Yan, G, Luna, A, Wang, H, Bozorgui, B, Li, X, Sanchez, M, Dereli, Z, Kahraman, N, Kara, G, Chen, X, Zheng, C, McGrail, D, Sahni, N, Lu, Y, Babur, O, Cokol, M, Lim, B, Ozpolat, B, Sander, C, Mills, GB & Korkut, A 2022, , Cell Reports, vol. 40, no. 11, 111304, pp. 111304. https://doi.org/10.1016/j.celrep.2022.111304

Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304]
Rodriguez-Aguayo, C, Bayraktar, E, Ivan, C, Aslan, B, Mai, J, He, G, Mangala, LS, Jiang, D, Nagaraja, AS, Ozpolat, B, Chavez-Reyes, A, Ferrari, M, Mitra, R, Siddik, ZH, Shen, H, Yang, X, Sood, AK & Lopez-Berestein, G 2022, , EBioMedicine, vol. 83, 104194, pp. 104194. https://doi.org/10.1016/j.ebiom.2022.104194

miRacle of microRNA-Driven Cancer Nanotherapeutics
Kara, G, Arun, B, Calin, GA & Ozpolat, B 2022, , Cancers, vol. 14, no. 15, 3818. https://doi.org/10.3390/cancers14153818

Redirecting host preexisting influenza A virus immunity for cancer immunotherapy
Chaganty, BKR, Qiu, S, Lu, Y, Lopez-Berestein, G, Ozpolat, B & Fan, Z 2022, , Cancer Immunology, Immunotherapy, vol. 71, no. 7, pp. 1611-1623. https://doi.org/10.1007/s00262-021-03099-9

Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study
Butner, JD, Dogra, P, Chung, C, Ruiz-Ramírez, J, Nizzero, S, Plodinec, M, Li, X, Pan, PY, Chen, SH, Cristini, V, Ozpolat, B, Calin, GA & Wang, Z 2022, , Cell death & disease, vol. 13, no. 5, 485. https://doi.org/10.1038/s41419-022-04939-x, https://doi.org/10.1038/s41419-022-04939-x

RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G, Calin, GA & Ozpolat, B 2022, , Advanced Drug Delivery Reviews, vol. 182, 114113, pp. 114113. https://doi.org/10.1016/j.addr.2022.114113

miRNA-193b-5p Suppresses Pancreatic Cancer Cell Proliferation, Invasion, Epithelial Mesenchymal Transition, and Tumor Growth by Inhibiting eEF2K
Gurbuz, N, Kahraman, N, Sonmez, HE, Mokhlis, HA, Kosar, PA & Ozpolat, B 2022, , Anti-Cancer Agents in Medicinal Chemistry, vol. 22, no. 14, pp. 2607-2618. https://doi.org/10.2174/1871520622666220117123213

CORRIGENDUM: GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma
El-Arabey, AA, Denizli, M, Kanlikilicer, P, Bayraktar, R, Ivan, C, Rashed, M, Kabil, N, Ozpolat, B, Calin, GA, Salama, SA, Abd-Allah, AR, Sood, AK & Lopez-Berestein, G 2022, , Cellular Signalling, vol. 89, 110147, pp. 110147. https://doi.org/10.1016/j.cellsig.2021.110147